



Tumor Models and Drug Targeting In Vitro

Guest Editors:

Dr. Sascha Kopp

Bioreactors and Applied
Microgravity Research,
Department for Microgravity and
Translational Regenerative
Medicine, Clinic for Plastic,
Aesthetic and Hand Surgery,
Otto-von-Guericke University,
39120 Magdeburg, Germany

Dr. Marcus Krüger

Environmental Cell Biology
Group, Department of
Microgravity and Translational
Regenerative Medicine, Otto von
Guericke University, 39106
Magdeburg, Germany

Deadline for manuscript
submissions:

closed (15 September 2022)

Message from the Guest Editors

Dear Colleagues,

Meaningful preclinical models are of extremely great importance for new therapeutic approaches against cancers. Far too often, promising substances fail in later clinical trials. Therefore, it is appropriate to use the advantages of advanced in vitro models to enhance the clinical success of drugs identified in basic research by better predicting their responses in patients.

Today, technological and scientific developments allow researchers to better understand the complex biology of cancer and the molecular relationships in tumors and during metastasis. Particularly, three-dimensional tumor and metastatic models, closely mimicking the in vivo tumor tissue, have become an indispensable platform for investigating the tumor microenvironment, mechanical properties, biochemical factors, as well as dynamic cell–cell and cell–ECM interactions. These offer unique advantages in fundamental and clinical biomedical studies as well as in drug development.

This Special Issue aims to highlight recent advances in the development and applications of in vitro tumor models. We welcome the submission of original research and review manuscripts.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)